Novo's CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1 presented at ObesityWeek® 2026
A real announcement email from Novo Nordisk. Captured November 15, 2026.
Make this email yours
Migma AI designs one like it with your logo, colors, and images.

About this email
Captured Announcement
Novo Nordisk announces clinical trial results from REDEFINE 1 showing weight loss outcomes with investigational CagriSema at ObesityWeek 2026.
Standard corporate press release format with top-left company logo, bulleted executive summary, clinical study narrative, data tables, and PR contact footer.
Explore similar emails
Color palette
Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.